TScan Therapeutics, Inc. reports clinical and corporate developments for its T cell receptor-engineered T cell therapy pipeline. The company’s cancer programs include TSC-101 in the ALLOHA heme trial for patients with hematologic malignancies undergoing allogeneic hematopoietic cell transplantation, and CD45-targeted candidates TSC-102-A01 and TSC-102-A03 with cleared IND applications.
Recurring TCRX updates cover clinical data presentations, trial enrollment and manufacturing-process updates, FDA interactions, financial results, healthcare conference participation, and portfolio priorities. The company also describes early work in in vivo engineering for solid tumors and target discovery in T cell-mediated autoimmune disorders.
TScan Therapeutics, Inc. (Nasdaq: TCRX) has appointed Zoran Zdraveski, J.D., Ph.D., as Chief Legal Officer. With over 20 years of experience in corporate law and business operations in the biopharmaceutical sector, Zdraveski is expected to significantly contribute to TScan’s efforts in advancing their T-cell receptor engineered therapies for cancer treatment. His expertise includes building intellectual property portfolios, which is crucial as TScan develops therapies targeting novel cancer antigens.
WALTHAM, Mass., Sept. 02, 2021 – TScan Therapeutics (Nasdaq: TCRX) announced that its CEO, David Southwell, will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on September 10, 2021, at 4:15 p.m. ET. A live webcast of the event will be accessible on the company’s website, with an archived replay available post-event.
TScan Therapeutics focuses on developing T-cell receptor engineered therapies for cancer treatment, including TSC-100 and TSC-101 for hematologic malignancies.
TScan Therapeutics has debuted as a publicly traded company on Nasdaq under the ticker TCRX after raising $100 million in its IPO to fuel its TCR-T therapy programs for liquid and solid tumors. The company aims to submit IND applications for lead candidates TSC-100 and TSC-101 in Q4 2021, with clinical trials anticipated in H1 2022. Financial results show a net loss of $10.7 million for Q2 2021, up from $5.6 million in Q2 2020, but the cash position remains strong at $106.2 million, extending their runway into 2024.
TScan Therapeutics (Nasdaq: TCRX) announced advancements in next-generation SARS-CoV-2 vaccine research, focusing on T-cell targets discovered in recovering COVID-19 patients. Gavin MacBeath, Ph.D., will present these findings at the Cell-Mediated Therapies for Infectious Disease Summit on July 22, 2021. The research identified conserved epitope targets outside the Spike protein, showing promise in in vitro studies for second-generation vaccines. TScan has licensed these targets to QIAGEN and Poseida Therapeutics for further development of T-cell therapies and tests.
TScan Therapeutics announced the pricing of its initial public offering (IPO) on July 15, 2021, of 6,666,667 shares at a price of $15.00 each, raising $100 million before expenses. The offering will close around July 20, 2021, pending customary conditions. An additional 1,000,000 shares may be purchased by underwriters within 30 days. The stock is set to trade on Nasdaq under the symbol TCRX starting July 16, 2021. The company specializes in T-cell receptor-engineered therapies for cancer treatment.